KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.

Hanrong Cheng, Liying Deng, Zili Meng, Wei Zhang, Tao Chen, Rui Chen, Shiyou Tang, Yunhui Lv, Xiaoli Su, Zhifen Liu, Xiaoqing Zhang, Xueyi Wang, Hongjing Mao, Nuofu Zhang, Huan Yu, Jiyang Pan, Yuping Xie, Jiyou Tang, Shankai Yin, Zan Wang, Maoqing Tong, Shuqin Zhan, Chunxue Wang, Bei Wang, Weihua Zhang, Weifeng Mi, Lin Lu

CNS Drugs 40(1) 83-98

PMID41128833
PMCIDPMC12769595
DOI10.1007/s40263-025-01232-1
发表日期2025-10-23
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:非 KM 图。
摘要

摘要

BACKGROUND AND OBJECTIVES: Excessive daytime sleepiness (EDS) is a prominent symptom of obstructive sleep apnea (OSA), negatively affecting patients' quality of life. The objective of this study was to assess the efficacy and safety of solriamfetol in patients with OSA with EDS from China. METHODS: This multicenter, randomized, double-blind, placebo-controlled phase 3 trial compared solriamfetol (75/150 mg once daily) with placebo for 12 weeks. Adults diagnosed with OSA, mean Maintenance of Wakefulness Test (MWT) sleep latency < 30 min, and Epworth Sleepiness Scale (ESS) score ≥ 10 were included. Patients with disorders causing EDS other than OSA were excluded. Co-primary endpoints were change from baseline to week 12 in MWT mean sleep latency and ESS score; a key secondary endpoint was improvement on Patient Global Impression of Change (PGI-C), assessed on a seven-point scale. MWT was performed at baseline and at weeks 2, 5, and 12, whereas the ESS and PGI-C were evaluated at weeks 2, 5, 8, and 12. Safety and tolerability were assessed on the basis of treatment-emergent adverse events (TEAEs), laboratory tests, vital signs, 24-h ambulatory blood pressure monitoring, 12-lead electrocardiogram, and physical examination. Statistical analyses of co-primary endpoints were performed on the full analysis set (FAS) using a mixed model for repeated measures (MMRM). Safety analyses were performed on the safety population. A hierarchical testing sequence was used to control multiplicity. RESULTS: Of the 204 patients randomized (1:1) into placebo and solriamfetol groups, 192 completed the study (96 in each group). Co-primary endpoints were met, with significantly increased mean MWT sleep latency (P < 0.0001) and decreased ESS score (P = 0.0017) in the solriamfetol group (MWT, n = 95; ESS, n = 97) versus placebo (MWT, n = 95; ESS, n = 96) at week 12. Higher proportion of participants receiving solriamfetol (n = 90; 89.1%) reported improvement in PGI-C versus placebo (n = 77; 77.0%; P = 0.0221). At least one TEAE was reported in solriamfetol (n = 84; 82.4%) and placebo (n = 67; 65.7%) groups. The occurrence of serious TEAEs was low, with one incidence in both groups. Most frequently reported TEAEs in solriamfetol group included upper respiratory tract infection, dizziness, hyperuricemia, hypertension, hyperlipidemia, hypertriglyceridemia, and increased blood creatine phosphokinase. Most TEAEs were of mild/moderate severity and did not lead to study treatment discontinuation. CONCLUSIONS: Solriamfetol demonstrated substantial efficacy and acceptable safety in Chinese patients with OSA with EDS, reinforcing its role as a viable treatment option. TRIAL REGISTRATION: ClinicalTrials.gov: NCT06103825.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study design. The double-blind treatment period included a titration phase and a maintenance phase. During the titration phase, study participants were titrated to the maximal treatment dose that was tolerated, which may have included the following three scenarios: (1) The participants were administered the treatment 37.5 mg once daily (QD) on days 1–3, and 75 mg QD starting from day 4. For participants who could not tolerate, changes in dosing back to 37.5 mg QD were permitted on the basis of tolerability. Participants should be discontinued from the study if they could not tolerate 37.5 mg. During the first week, the participants who down-titrated to 37.5 mg from 75 mg QD were required to complete safety assessment after receiving 37.5 mg QD for at least 3 days. The dosage was increased to 75 mg QD starting from the first day of the second week and was to remain stable at 75 mg until the end of the double-blind treatment period. If the participant showed intolerance to 75 mg and a down-titration was required, then he/she should be discontinued from the study. (2) The participants received 37.5 mg QD from days 1 to 3, followed by 75 mg QD from days 4 to 7. Study participants without dose reduction during the first week were up-titrated to 150 mg QD starting on week 2, after completing safety assessments at the end of the first week. If participants were intolerant to 150 mg QD, the dosage could be reduced to 75 mg QD. If a further down-titration from 75 mg to 37.5 mg QD was needed, then they should be withdrawn from the study. Starting from the fourth day of the second week onward, the dosage of the study drug should remain stable at 75 mg QD until the end of the double-blind treatment period. (3) The participants received 37.5 mg QD from days 1 to 3 followed by 75 mg QD from days 4 to 7. After week 1 safety assessments, the study dose was titrated to 150 mg QD starting on week 2 and continued through the double-blind treatment period.
非 KM Figure
Fig. 2Patient disposition flow chart
非 KM Figure
Fig. 3Least squares mean change in Maintenance of Wakefulness Test sleep latency from baseline over 12 weeks (full analysis set)
非 KM Figure
Fig. 4Least squares mean change in Epworth Sleepiness Scale from baseline over 12 weeks (full analysis set)
非 KM Figure
Fig. 5Least squares mean change from baseline in sleep latency for each of the individual Maintenance of Wakefulness Test (MWT) trials at week 12 (full analysis set)
非 KM Figure